Literature DB >> 11406605

Positional dissociation between the genetic mutation responsible for pseudohypoparathyroidism type Ib and the associated methylation defect at exon A/B: evidence for a long-range regulatory element within the imprinted GNAS1 locus.

M Bastepe1, J E Pincus, T Sugimoto, K Tojo, M Kanatani, Y Azuma, K Kruse, A L Rosenbloom, H Koshiyama, H Jüppner.   

Abstract

Pseudohypoparathyroidism type Ib (PHP-Ib) is a paternally imprinted disorder which maps to a region on chromosome 20q13.3 that comprises GNAS1 at its telomeric boundary. Exon A/B of this gene was recently shown to display a loss of methylation in several PHP-Ib patients. In nine unrelated PHP-Ib kindreds, in whom haplotype analysis and mode of inheritance provided no evidence against linkage to this chromosomal region, we confirmed lack of exon A/B methylation for affected individuals, while unaffected carriers showed no epigenetic abnormality at this locus. However, affected individuals in one kindred (Y2) displayed additional methylation defects involving exons NESP55, AS and XL, and unaffected carriers in this family showed an abnormal methylation at exon NESP55, but not at other exons. Taken together, current evidence thus suggests that distinct mutations within or close to GNAS1 can lead to PHP-Ib and the associated epigenetic changes. To further delineate the telomeric boundary of the PHP-Ib locus, the previously reported kindred F, in which patient F-V/51 is recombinant within GNAS1, was investigated with several new markers and direct nucleotide sequence analysis. These studies revealed that F-V/51 remains recombinant at a single nucleotide polymorphism (SNP) located 1.2 kb upstream of XL. No heterozygous mutation was identified between exon XL and an SNP approximately 8 kb upstream of NESP55, where this affected individual becomes linked, suggesting that the genetic defect responsible for parathyroid hormone resistance in kindred F, and probably other PHP-Ib patients, is located >or=56 kb centromeric of the abnormally methylated exon A/B. A region upstream of the known coding exons of GNAS1 is therefore predicted to exert, presumably through imprinting of exon A/B, long-range effects on G(s)alpha expression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11406605     DOI: 10.1093/hmg/10.12.1231

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  36 in total

1.  Discordance between genetic and epigenetic defects in pseudohypoparathyroidism type 1b revealed by inconsistent loss of maternal imprinting at GNAS1.

Authors:  Suzanne Jan de Beur; Changlin Ding; Emily Germain-Lee; Justin Cho; Alexander Maret; Michael A Levine
Journal:  Am J Hum Genet       Date:  2003-07-11       Impact factor: 11.025

2.  Analysis of Multiple Families With Single Individuals Affected by Pseudohypoparathyroidism Type Ib (PHP1B) Reveals Only One Novel Maternally Inherited GNAS Deletion.

Authors:  Rieko Takatani; Angelo Molinaro; Giedre Grigelioniene; Olta Tafaj; Tomoyuki Watanabe; Monica Reyes; Amita Sharma; Vibha Singhal; F Lucy Raymond; Agnès Linglart; Harald Jüppner
Journal:  J Bone Miner Res       Date:  2015-11-14       Impact factor: 6.741

3.  A Large Inversion Involving GNAS Exon A/B and All Exons Encoding Gsα Is Associated With Autosomal Dominant Pseudohypoparathyroidism Type Ib (PHP1B).

Authors:  Giedre Grigelioniene; Pasi I Nevalainen; Monica Reyes; Susanne Thiele; Olta Tafaj; Angelo Molinaro; Rieko Takatani; Marja Ala-Houhala; Daniel Nilsson; Jesper Eisfeldt; Anna Lindstrand; Marie-Laure Kottler; Outi Mäkitie; Harald Jüppner
Journal:  J Bone Miner Res       Date:  2017-02-24       Impact factor: 6.741

4.  A novel deletion involving GNAS exon 1 causes PHP1A and further refines the region required for normal methylation at exon A/B.

Authors:  Monica Reyes; Anara Karaca; Murat Bastepe; Nese Ersoz Gulcelik; Harald Jüppner
Journal:  Bone       Date:  2017-07-12       Impact factor: 4.398

5.  Clinical heterogeneity of familial pseudohypoparathyroidism.

Authors:  L Foppiani; P Del Monte; F Faravelli; L de Sanctis; A Marugo; D Bernasconi
Journal:  J Endocrinol Invest       Date:  2006-01       Impact factor: 4.256

Review 6.  The role of GNAS and other imprinted genes in the development of obesity.

Authors:  L S Weinstein; T Xie; A Qasem; J Wang; M Chen
Journal:  Int J Obes (Lond)       Date:  2009-10-20       Impact factor: 5.095

7.  Parathyroid hormone signaling via Gαs is selectively inhibited by an NH(2)-terminally truncated Gαs: implications for pseudohypoparathyroidism.

Authors:  Svetlana Puzhko; Cynthia Gates Goodyer; Mohammad Amin Kerachian; Lucie Canaff; Madhusmita Misra; Harald Jüppner; Murat Bastepe; Geoffrey N Hendy
Journal:  J Bone Miner Res       Date:  2011-10       Impact factor: 6.741

8.  Similar frequency of paternal uniparental disomy involving chromosome 20q (patUPD20q) in Japanese and Caucasian patients affected by sporadic pseudohypoparathyroidism type Ib (sporPHP1B).

Authors:  Rieko Takatani; Masanori Minagawa; Angelo Molinaro; Monica Reyes; Kaori Kinoshita; Tomozumi Takatani; Itsuro Kazukawa; Misako Nagatsuma; Kenichi Kashimada; Kenichi Sato; Kazuyuki Matsushita; Fumio Nomura; Naoki Shimojo; Harald Jüppner
Journal:  Bone       Date:  2015-05-19       Impact factor: 4.398

9.  Imprinting status of Galpha(s), NESP55, and XLalphas in cell cultures derived from human embryonic germ cells: GNAS imprinting in human embryonic germ cells.

Authors:  Janet L Crane; Michael J Shamblott; Joyce Axelman; Stephanie Hsu; Michael A Levine; Emily L Germain-Lee
Journal:  Clin Transl Sci       Date:  2009-10       Impact factor: 4.689

10.  Intragenic GNAS deletion involving exon A/B in pseudohypoparathyroidism type 1A resulting in an apparent loss of exon A/B methylation: potential for misdiagnosis of pseudohypoparathyroidism type 1B.

Authors:  Eduardo Fernandez-Rebollo; Beatriz García-Cuartero; Intza Garin; Cristina Largo; Francisco Martínez; Concepcion Garcia-Lacalle; Luis Castaño; Murat Bastepe; Guiomar Pérez de Nanclares
Journal:  J Clin Endocrinol Metab       Date:  2009-12-11       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.